Barclays Reiterates Overweight Rating on Spring Works Therapeutics (SWTX)

Barclays analyst Peter Lawson reiterated an Overweight rating and $63.00 price target on Spring Works Therapeutics (NASDAQ: SWTX).

The analyst commented, "SpringWorks completed the rolling NDA submission for mirdametinib (MEK inhibitor) in NF1-PN - in line with recent management guidance - see details below from our recent NDR with SpringWorks. We would expect priority review, which could put a potential FDA approval sometime in early 2025."

For an analyst ratings summary and ratings history on Spring Works Therapeutics click here. For more ratings news on Spring Works Therapeutics click here.

Shares of Spring Works Therapeutics closed at $38.53 yesterday.

You May Also Be Interested In

• Freedom Broker Downgrades HF Sinclair (DINO) to Sell
• First Commonwealth Financial (FCF) Tops Q2 EPS by 1c
• Ashland (ASH) Tops Q3 EPS by 2c; offers guidance